GNLKQ logo

GeneLink, Inc. (GNLKQ) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

GeneLink, Inc. (GNLKQ), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 49/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 18 Mar 2026
49/100 AI Puanı

GeneLink, Inc. (GNLKQ) Sağlık ve Boru Hattı Genel Bakışı

CEOBernard L. Kasten Jr.
MerkezOrlando, US
Halka Arz Yılı1998
SektörHealthcare

GeneLink, Inc., founded in 1994, provides personalized health solutions through DNA assessment services, custom supplements, and skincare products. Operating in the biotechnology sector, the company focuses on individualized wellness, but faces challenges with profitability and OTC market risks, reflected in its negative P/E ratio and significant beta.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 18 Mar 2026

Yatırım Tezi

Investing in GeneLink, Inc. (GNLKQ) presents a high-risk, high-reward scenario. The company's focus on personalized health solutions through DNA assessment services aligns with growing consumer interest in preventative and individualized healthcare. However, the company's negative P/E ratio and significant beta of -157.42 indicate substantial financial instability and volatility. Growth catalysts may include expanding its product line and strategic partnerships to broaden market reach. Key value drivers would be achieving profitability and demonstrating sustainable revenue growth. The OTC market listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully weigh the potential for growth in the personalized health market against the company's current financial challenges and the risks associated with OTC trading.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
  • P/E Ratio of -0.00 reflects that the company is not currently profitable.
  • Profit Margin of -142.9% demonstrates significant losses relative to revenue.
  • Gross Margin of 21.8% suggests some ability to generate profit from sales before operating expenses.
  • Beta of -157.42 indicates an inverse correlation to the market, but also suggests high volatility and potential instability.

Rakipler & Benzerleri

Güçlü Yönler

  • Personalized health solutions based on DNA assessment.
  • Customized supplement formulations.
  • Proprietary technology for DNA analysis.
  • Direct-to-consumer sales model.

Zayıflıklar

  • Negative profit margin and financial instability.
  • Limited market capitalization.
  • OTC market listing with associated risks.
  • Dependence on a niche market.

Katalizörler

  • Upcoming: Potential partnerships with healthcare providers to expand distribution channels.
  • Upcoming: Launch of new DNA assessment services targeting specific health concerns.
  • Ongoing: Direct-to-consumer marketing efforts to increase brand awareness and drive sales.

Riskler

  • Potential: Increased competition from established players in the biotechnology sector.
  • Potential: Regulatory changes affecting DNA assessment and supplement industries.
  • Ongoing: Negative profit margin and financial instability.
  • Ongoing: OTC market listing with associated risks.

Büyüme Fırsatları

  • Expanding Product Line: GeneLink can expand its product line to include more specialized DNA assessments and personalized health solutions. The global nutrigenomics market, which includes personalized nutrition based on genetic information, is projected to reach $1.2 billion by 2027. By introducing new products tailored to specific health concerns, GeneLink can attract a broader customer base and increase revenue. Timeline: 12-18 months to develop and launch new products.
  • Strategic Partnerships: Forming strategic partnerships with healthcare providers, wellness centers, and fitness companies can expand GeneLink's distribution channels and reach new customers. Collaborating with established players in the health and wellness industry can provide access to a wider audience and enhance credibility. The market for health and wellness partnerships is growing, with companies increasingly seeking to offer integrated solutions to their customers. Timeline: 6-12 months to establish partnerships.
  • International Expansion: Expanding into international markets can significantly increase GeneLink's customer base and revenue potential. The global market for personalized medicine is growing rapidly, with significant opportunities in Asia and Europe. By adapting its products and marketing strategies to local markets, GeneLink can tap into new sources of growth. Timeline: 18-24 months to establish international operations.
  • Direct-to-Consumer Marketing: Enhancing its direct-to-consumer marketing efforts can increase brand awareness and drive sales. Utilizing digital marketing channels, social media, and influencer marketing can effectively reach target customers and promote GeneLink's products. The market for direct-to-consumer healthcare products is growing, with consumers increasingly seeking convenient and accessible solutions. Timeline: Ongoing, with continuous optimization of marketing strategies.
  • Data Analytics and Personalization: Leveraging data analytics to further personalize its products and services can enhance customer satisfaction and loyalty. By analyzing customer data and genetic information, GeneLink can provide more tailored recommendations and solutions. The market for personalized healthcare is driven by the increasing availability of data and advancements in data analytics technologies. Timeline: Ongoing, with continuous improvement of data analytics capabilities.

Fırsatlar

  • Expanding product line to include more specialized DNA assessments.
  • Forming strategic partnerships with healthcare providers.
  • Expanding into international markets.
  • Leveraging data analytics to further personalize products and services.

Tehditler

  • Competition from established players in the biotechnology sector.
  • Regulatory changes affecting DNA assessment and supplement industries.
  • Economic downturn impacting consumer spending on personalized health solutions.
  • Negative publicity or scientific studies questioning the effectiveness of DNA-based personalized health.

Rekabet Avantajları

  • Proprietary DNA assessment technology.
  • Customized supplement formulations based on genetic information.
  • Personalized skincare product line.
  • Focus on individualized health solutions.

GNLKQ Hakkında

GeneLink, Inc., established in 1994 and based in Orlando, Florida, operates within the healthcare sector, specifically in biotechnology. The company focuses on personalized health solutions, primarily offering 12-gene DNA assessment services. These assessments are designed to provide insights into an individual's genetic predispositions, which GeneLink then uses to formulate health custom supplements tailored to the individual's needs. In addition to supplements, GeneLink formulates and markets a line of skin care products also designed with personalized health in mind. GeneLink's business model centers around leveraging genetic information to create individualized health and wellness products. The company caters to consumers interested in proactive and personalized healthcare solutions. However, it currently faces challenges related to profitability, as indicated by its negative profit margin of -142.9%.

Ne Yaparlar

  • Offers 12-gene DNA assessment services to provide insights into individual genetic predispositions.
  • Formulates health custom supplements based on DNA assessment results.
  • Develops and markets a line of skin care products.
  • Provides personalized health solutions tailored to individual needs.
  • Utilizes genetic information to create individualized health and wellness products.
  • Caters to consumers interested in proactive and personalized healthcare solutions.

İş Modeli

  • Generates revenue through the sale of DNA assessment services.
  • Generates revenue through the sale of custom supplements formulated based on DNA assessment results.
  • Generates revenue through the sale of skin care products.
  • Focuses on direct-to-consumer sales through online channels.

Sektör Bağlamı

GeneLink, Inc. operates in the rapidly evolving biotechnology sector, which is characterized by innovation and personalized medicine. The market for personalized health solutions, including DNA assessment and custom supplements, is growing, driven by increasing consumer awareness and technological advancements. However, the industry is also highly competitive, with numerous companies offering similar services. GeneLink faces competition from established players and emerging startups. The company's success depends on its ability to differentiate its products, effectively market its services, and navigate the complex regulatory landscape of the healthcare industry.

Kilit Müşteriler

  • Individuals interested in personalized health and wellness solutions.
  • Consumers seeking proactive healthcare options.
  • People looking for customized supplements and skincare products.
  • Customers who value genetic insights for health management.
AI Güveni: 69% Güncellendi: 18 Mar 2026

Finansallar

Grafik & Bilgi

GeneLink, Inc. (GNLKQ) hisse senedi fiyatı: Price data unavailable

Son Haberler

GNLKQ için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

GNLKQ için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

GNLKQ için Wall Street fiyat hedefi analizi.

MoonshotScore

49/100

Bu puan ne anlama geliyor?

MoonshotScore, GNLKQ'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Bernard L. Kasten Jr.

CEO

Bernard L. Kasten Jr. serves as the CEO of GeneLink, Inc. His background includes experience in the healthcare and biotechnology sectors. He has held various leadership positions in companies focused on developing and marketing innovative health solutions. His expertise lies in strategic planning, product development, and market expansion. He is responsible for guiding GeneLink's overall strategy and ensuring the company's growth and profitability.

Sicil: Under Bernard L. Kasten Jr.'s leadership, GeneLink has focused on expanding its product line and enhancing its direct-to-consumer marketing efforts. Key milestones include the development of new DNA assessment services and the launch of personalized skincare products. However, the company continues to face challenges related to profitability and financial stability.

GNLKQ OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that GeneLink may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for GNLKQ is likely very limited, typical for OTC Other stocks. This means that trading volume is low, and the bid-ask spread (the difference between the buying and selling price) can be wide. It may be difficult to buy or sell shares quickly without significantly affecting the price. Investors should be prepared for potential delays in executing trades and the possibility of incurring higher transaction costs.
OTC Risk Faktörleri:
  • Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
  • Lack of Transparency: Limited financial disclosure and regulatory oversight.
  • Price Volatility: High price fluctuations due to speculative trading and limited market depth.
  • Potential for Fraud: Increased risk of fraudulent activities due to less stringent listing requirements.
  • Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial instability.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and audit reports.
  • Research the background and experience of the company's management team.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance and legal standing.
  • Monitor the company's trading volume and price activity.
  • Consult with a qualified financial advisor before investing.
  • Understand the risks associated with OTC trading.
Meşruiyet Sinyalleri:
  • Company has been in operation since 1994.
  • Offers DNA assessment services, custom supplements, and skincare products.
  • Has a CEO in place.
  • Operates in the healthcare sector.

GeneLink, Inc. Hissesi: Cevaplanan Temel Sorular

GNLKQ için değerlendirilmesi gereken temel faktörler nelerdir?

GeneLink, Inc. (GNLKQ) şu anda yapay zeka skoru 49/100, düşük puanı gösteriyor. Temel güçlü yan: Personalized health solutions based on DNA assessment.. İzlenmesi gereken birincil risk: Potential: Increased competition from established players in the biotechnology sector.. Bu bir finansal tavsiye değildir.

GNLKQ MoonshotScore'u nedir?

GNLKQ şu anda MoonshotScore'da 49/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

GNLKQ verileri ne sıklıkla güncellenir?

GNLKQ fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler GNLKQ hakkında ne diyor?

GNLKQ için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

GNLKQ'a yatırım yapmanın riskleri nelerdir?

GNLKQ için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Increased competition from established players in the biotechnology sector.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

GNLKQ'ın P/E oranı nedir?

GNLKQ için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GNLKQ'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

GNLKQ aşırı değerli mi, yoksa düşük değerli mi?

GeneLink, Inc. (GNLKQ)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

GNLKQ'ın temettü verimi nedir?

GeneLink, Inc. (GNLKQ) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data is based on the most recent available information.
  • OTC market data may be limited and subject to change.
Veri Kaynakları

Popüler Hisseler